Cybin D/B/A Helus Pharma (HELP)Healthcare | Biotechnology | Toronto, Canada | NasdaqGM
5.50 USD
After hours: 5.46 -0.04 (-0.040%) ⇩ (April 17, 2026, 7:58 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:35 p.m. EDT
Despite a toxic fundamental bottom (negative earnings, massive cash burn, and failed R&D history), HELUS Pharma (HELP) is showing pure speculative momentum driven by the rebranding narrative and positive Phase 2 anxiety trial data. The stock is trending above its 50-day average with speculative call flow widening the gap between sentiment (strong buy recommendations not yet reflected in price relative to targets) and trader positioning. This is a high-risk, event-driven momentum play rather than a value opportunity; the only downside risk is a clinical miss or regulatory rejection. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.237027 |
| AutoARIMA | 0.238829 |
| AutoETS | 0.238830 |
| AutoTheta | 0.316750 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 11.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.288 |
| Excess Kurtosis | -1.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 274,417,728 |
| Forward P/E | -1.71 |
| Beta | 1.04 |
| Website | https://cybin.com |
As of April 18, 2026, 11:35 p.m. EDT: Speculators exhibit a distinctly bullish near-term bias in the 1-3 month window (May/Aug 2026), evidenced by significantly higher Open Interest (OI) and volume on call strikes (5.0, 7.5, 10.0) compared to put strikes above the money. In the longer seaons (Dec 2026), call OI remains robust at distant strikes (12.5), while put activity appears interest at the 2.5 strike, suggesting a bullish bias. Implied volatility is elevated but varies across strikes, reflecting uncertainty around the pending Phase 2 anxiety data. Overall, option flow suggests bets are currently placed on upside momentum without heavy hedge protection.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24554181 |
| Address1 | 100 King Street West |
| Address2 | Suite 5600 |
| All Time High | 128.44 |
| All Time Low | 2.964 |
| Ask | 5.54 |
| Ask Size | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 672,460 |
| Average Daily Volume3 Month | 818,549 |
| Average Volume | 818,549 |
| Average Volume10Days | 672,460 |
| Beta | 1.04 |
| Bid | 5.46 |
| Bid Size | 6 |
| Book Value | 5.49 |
| City | Toronto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.5 |
| Current Ratio | 13.778 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.79 |
| Day Low | 5.45 |
| Display Name | Cybin |
| Earnings Timestamp | 1,770,989,400 |
| Earnings Timestamp End | 1,770,989,400 |
| Earnings Timestamp Start | 1,770,989,400 |
| Ebitda | -119,248,656 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.061 |
| Enterprise Value | 722,767,552 |
| Eps Current Year | -5.2372 |
| Eps Forward | -3.2091064 |
| Eps Trailing Twelve Months | -4.3 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.7684 |
| Fifty Day Average Change | -0.2684002 |
| Fifty Day Average Change Percent | -0.046529397 |
| Fifty Two Week Change Percent | -24.55418 |
| Fifty Two Week High | 9.83 |
| Fifty Two Week High Change | -4.33 |
| Fifty Two Week High Change Percent | -0.4404883 |
| Fifty Two Week Low | 4.29 |
| Fifty Two Week Low Change | 1.21 |
| Fifty Two Week Low Change Percent | 0.2820513 |
| Fifty Two Week Range | 4.29 - 9.83 |
| Financial Currency | CAD |
| First Trade Date Milliseconds | 1,568,381,400,000 |
| Float Shares | 90,785,802 |
| Forward Eps | -3.2091064 |
| Forward P E | -1.7138727 |
| Free Cashflow | -69,987,976 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 50 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.057290003 |
| Held Percent Institutions | 0.59665 |
| Implied Shares Outstanding | 49,894,131 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-01-05 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,743,379,200 |
| Last Split Date | 1,726,704,000 |
| Last Split Factor | 1:38 |
| Long Business Summary | Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. |
| Long Name | Cybin D/B/A Helus Pharma |
| Market | us_market |
| Market Cap | 274,417,728 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_666815486 |
| Most Recent Quarter | 1,604,102,400 |
| Net Income To Common | -123,217,320 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 273,162,537 |
| Number Of Analyst Opinions | 8 |
| Open | 5.65 |
| Operating Cashflow | -112,266,232 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 908-764-8385 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -0.72727203 |
| Post Market Price | 5.46 |
| Post Market Time | 1,776,470,289 |
| Previous Close | 5.5 |
| Price Eps Current Year | -1.0501795 |
| Price Hint | 2 |
| Price To Book | 1.0018215 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.356 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 5.79 |
| Regular Market Day Low | 5.45 |
| Regular Market Day Range | 5.45 - 5.79 |
| Regular Market Open | 5.65 |
| Regular Market Previous Close | 5.5 |
| Regular Market Price | 5.5 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 984,478 |
| Return On Assets | -0.31948 |
| Return On Equity | -0.55893004 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 49,894,131 |
| Shares Percent Shares Out | 0.0685 |
| Shares Short | 3,535,114 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,320,808 |
| Short Name | Cybin Inc. |
| Short Ratio | 2.79 |
| Source Interval | 15 |
| State | ON |
| Symbol | HELP |
| Target High Price | 94.44383 |
| Target Low Price | 8.067424 |
| Target Mean Price | 43.874058 |
| Target Median Price | 46.04805 |
| Total Cash | 206,357 |
| Total Cash Per Share | 0.002 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.57405 |
| Two Hundred Day Average Change | -1.07405 |
| Two Hundred Day Average Change Percent | -0.16337721 |
| Type Disp | Equity |
| Volume | 984,478 |
| Website | https://cybin.com |
| Zip | M5X 1C9 |